Intellect Neurosciences shares jump 25% Print E-mail
By Staff and Wire Reports   
Wednesday, 20 July 2011 15:54
best Penny stocksShares of Intellect Neurosciences, Inc (OTCBB:ILNS) jumped 25% on nearly four times the daily average volume after we told our premium subscribers about credible chatter involving a possible new patent milestone for the company.

ILNS-- one of our favorite biotech "lottery" penny plays-- holds key licensing deals with all the major players involved in various late-stage clinical trials investigating various potential blockbuster drugs which migh hold the key to cure or treat Alzheimers. Since we first covered the ILNS story last year, trading volume/interest has been extremely high, but a toxic financing deal sent shares to the sub-penny level.

The science and technology platforms at the company are solid (see video below), but one big question remains: "Can ILNS maximize shareholder value while they wait for some of the big, ongoing Phase III Bapineuzemab trials play out?"

Several big pharma players have been circling around the company, looking perhaps to jump in to the race to cure Alzheimers with Dr. Daniel Chain's ANTISENILIN® monoclonal antibody technology. Invented fourteen years ago, the innovative scientific discovery targets beta amyloid, a protein widely believed to be an important contributor to the cognitive deficits seen in Alzheimer’s disease.

Importantly, ANTISENILIN® antibodies bind the major classes of beta amyloid, including soluble and plaque-bound forms, but avoid binding to the amyloid precursor protein from which beta amyloid is produced in the body. It is expected that this specificity may reduce the potential for adverse effects. Patents have been granted in Europe, Japan and several other countries with corresponding patent applications pending in the United States.



See our original coverage about the firm here:

ILNS has multiple stakes in $20 billion Alzheimer's space race

Bapineuzumab and Intellect Neurosciences Attracting Attention

Exclusive: Numerous false starts by others don't discourage company's search for Alzheimer's treatment

 

Disclosure: None



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter